Anaes Vivas · Anaesthetic adjuncts
Data viva — interpreting the metaraminol evidence base
A data viva on the metaraminol evidence. The pharmacology row (mixed-acting: direct alpha-1 agonism — Gq-coupled, phospholipase C to IP3 and DAG, raised intracellular calcium, vasoconstriction — PLUS indirect noradrenaline release from sympathetic nerve terminals; the released noradrenaline stimulates cardiac beta-1 receptors, so metaraminol maintains the cardiac output and does not produce the reflex bradycardia seen with phenylephrine; duration about 20 to 30 minutes, metabolised by monoamine oxidase; IV bolus 0.5 to 2 mg — taught pharmacology and kinetics). The push-dose row (da Silveira — retrospective cohort, n-349 septic ICU, push-dose metaraminol associated with less post-intubation hypotension, no mortality difference). The obstetric-BMI row (Gao — continuous-infusion ED50 1.84 versus 2.28 mg/h by maternal BMI; phenylephrine first-line on fetal-pH grounds — Lee 2002). The cost-and-environment row (Parkinson — stewardship scope only). The vasopressor-selection-in-the-elderly row (Dong — delirium nulls for the studied agents; metaraminol not studied). Interpret, rank by evidence strength, and translate into a clinical recommendation.
On this page
Study tools
Target exams
Stimulus
A table summarises the metaraminol evidence across five sources spanning pharmacology, a peri-induction cohort and special populations. The pharmacology row: metaraminol is a MIXED-ACTING agent — direct alpha-1 agonism (Gq-coupled receptor, phospholipase C to IP3 and DAG, raised intracellular calcium, arteriolar and venous vasoconstriction) PLUS indirect release of noradrenaline from sympathetic nerve terminals via the uptake-1 transporter; the released noradrenaline stimulates cardiac beta-1 receptors, so the blood pressure rises while the cardiac output is MAINTAINED or slightly INCREASED and there is no reflex bradycardia (the key difference from phenylephrine); the duration of a bolus is about 20 to 30 minutes and the dose is 0.5 to 2 mg intravenously, metabolised by monoamine oxidase (taught pharmacology and kinetics — no receptor or kinetic primary in-file). The push-dose row (da Silveira): a multicentre retrospective cohort (n-349 septic ICU patients) found push-dose metaraminol around induction associated with less post-intubation hypotension (21.1% versus 49.4%), with no mortality difference. The obstetric-BMI row (Gao): the continuous-infusion ED50 for preventing spinal-induced hypotension was 1.84 mg/h below BMI 30 versus 2.28 mg/h at 30 and above (n-80, single-centre); phenylephrine stays first-line on fetal-pH grounds (Lee 2002: higher UA pH, WMD +0.03 [6]). The cost-and-environment row (Parkinson): stewardship scope only — ampoules versus prefilled syringes, not drug efficacy. The older-adult row (Dong): delirium nulls for the studied agents (phenylephrine-versus-norepinephrine OR 0.97; ephedrine-versus-norepinephrine OR 0.74) — metaraminol was not studied, so no metaraminol-delirium claim is carried. Interpret the data, rank the evidence by strength, and justify a clinical choice in three scenarios.[1][2][6]
References5ShowHide
- [1]da Silveira F, et al. Avoidance of post-intubation arterial hypotension with push-dose metaraminol. Heart Lung, 2026.PMID 42173042
- [2]Gao X, et al. Effect of maternal BMI on the dosage of metaraminol for preventing hypotension. BMC Anesthesiol, 2026.PMID 42121030
- [3]Parkinson EA, et al. The Financial and Environmental Cost of Anaesthetic Emergency Drugs: Comparing Ampoules With Prefilled Syringes. Cureus, 2026.PMID 42005180
- [4]Dong T, et al. Vasopressor Selection and Postoperative Delirium in Older Adults. Semin Cardiothorac Vasc Anesth, 2026.PMID 42359892
- [6]Lee A, et al. A quantitative, systematic review of randomized controlled trials of ephedrine versus phenylephrine for the management of hypotension during spinal anesthesia for cesarean delivery. Anesth Analg, 2002.PMID 11916798